Competitor Analysis Report on PI3K-AKT-mTor Inhibitors -

Updated: March 2013

  The PI3K-AKT-mTOR pathway is a vital signal transduction cascade associated with many essential cellular activities, including growth and survival. Genetic alterations that disrupt this pathway have been implicated in a wide variety of human tumors. Targeting the three components of this pathway, either separately or in combination, has emerged as a key strategy for cancer treatment.

This report provides intelligence about PI3K-Akt-mTOR signaling cascade modulators. It includes information about new developments in the active Pre-clinical and Clinical pipeline of these modulators (as of March 2013), specifically for the treatment of cancer.

Research validating the therapeutic potential of targeting the PI3K/Akt/mTOR pathway for the cancer treatment, has led to a deluge of kinase inhibitors targeting significant knots of this pathway including phosphatidylinositol-3-kinase (PI3K), serine-threonine protein kinase Akt ((Akt or PKB) and mammalian target of rapamycin (mTOR]. These include both isoform specific as well as isoform non specific inhibitors. Investigational studies with these inhibitors are in various phases of Clinical trials after having proven preclinical safety and effectiveness.

The report presents a compilation of active projects in Pre-clinical and Clinical pipeline development of PI3K-AKT-mTOR inhibitors in Oncology. In addition, the report also lists company specific R&D pipelines of PI3K-AKT-mTOR inhibitors.


Table of Contents 

Description  3 

About the Author 4 

Pan PI3K inhibitors 5 

PI3K Isoform Specific Inhibitors 11 

mTOR Inhibitors 20 

Akt Inhibitors 48 

PI3K/mTOR Dual Inhibitors 56 

mTOR and Akt Inhibitor  66 

Others  68 

Figure 1: Target-Based PI3K-Akt-mTOR Inhibitors  69 

Figure 2: PI3K-Akt-mTOR Inhibitors Vs. Licensee 70 

Appendix 2: PI3K-Akt-mTOR Inhibitors R&D pipeline 73 

About Parthys Competitive Analysis 74 

About Parthys Reverse Informatics 74 

Contact Us  74